Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
We provide 1 form of Tafamidis
Tafamidis
594839-88-0
|
306.98
|
4.998
Tafamidis stabilizes transthyretin tetramers, reducing the amount of monomers available for amyloidogenesis. Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid | 2-(3,5-dichlorophenyl)-benzoxazole-6-carboxylic acid | 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid | 6-carboxy-2-(3,5-dichlorophenyl)benzoxazole | tafamidis | vyndaqel
Tafamidis stabilizes transthyretin tetramers, reducing the amount of monomers available for amyloidogenesis. Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid | 2-(3,5-dichlorophenyl)-benzoxazole-6-carboxylic acid | 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid | 6-carboxy-2-(3,5-dichlorophenyl)benzoxazole | tafamidis | vyndaqel
$42/5 mg
(EBC)
1
We provide 0 compound for Tafamidis